News Sentiment

MNPR sentiment intelligence

Monopar Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 106.60 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+9.0% over one week, +78.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 9.0% Price confirming higher
Trend fit Trend active 78.4% over four weeks
Fair value 247.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingView 9
Market source 8
GlobeNewswire 5
simplywall.st 3
Seeking Alpha 2
Stock Traders Daily 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 13
Balance sheet 2
Regulatory and legal 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
TradingView Direct company coverage

Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0

This article briefly presents a financial metric, "Price to book forward," for Monopar Therapeutics Inc (GETTEX:1IY0). The content indicates that market data and reference data are provided by ICE Data Services and FactSet, respectively. The page appears to be a financial data sn

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 00:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Monopar Therapeutics Inc. – NASDAQ:MNPR

This article displays financial data for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The content also notes that this information is provided by F

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 14:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0

The article provides financial data for Monopar Therapeutics Inc (GETTEX:1IY0), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The information is presented on a TradingView page, including an overview of financial

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR

This article provides financial information for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to revenue forward. It is presented in the context of TradingView, a financial platform offering various market data and analysis tools. The content include

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 07:09
Source
TradingView